American Journal of Rhinology & Allergy

Papers
(The H4-Index of American Journal of Rhinology & Allergy is 15. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
A Phase II, Multicenter, Randomized, Placebo-Controlled Study of Benralizumab, a Humanized Anti-IL-5R Alpha Monoclonal Antibody, in Patients With Eosinophilic Chronic Rhinosinusitis43
Diagnostic Criteria for Odontogenic Sinusitis: A Systematic Review37
Defining the Efficacy of Omalizumab in Nasal Polyposis: A POLYP 1 and POLYP 2 Subgroup Analysis28
Intensive Olfactory Training in Post-COVID-19 Patients: A Multicenter Randomized Clinical Trial24
Association of Air Pollutant Exposure and Sinonasal Histopathology Findings in Chronic Rhinosinusitis23
Temperature-Controlled Radiofrequency Neurolysis for the Treatment of Rhinitis23
COVID-19-Induced Anosmia and Ageusia Are Associated With Younger Age and Lower Blood Eosinophil Counts21
Qualitative Olfactory Dysfunction and COVID-19: An Evidence-Based Review with Recommendations for the Clinician21
Association Between Chemosensory Dysfunction and Diet Quality in United States Adults21
Regulation of the Expression of SARS-CoV-2 Receptor Angiotensin-Converting Enzyme 2 in Nasal Mucosa20
Effects of Probiotics on Allergic Rhinitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials20
Chronic rhinosinusitis with nasal polyposis (CRSwNP): the correlation between expression of Galectin-10 and Clinical-Cytological Grading (CCG)19
Effects of Omalizumab Treatment in Patients With Recalcitrant Nasal Polyposis and Mild Asthma: A Multicenter Retrospective Study17
Effect of Medical Therapy in Allergic Rhinitis: A Systematic Review and Meta-Analysis16
Olfactory-related Quality of Life Adjustments in Smell Loss during the Coronavirus-19 Pandemic15
Nasal Nitric Oxide and Nasal Cytology as Predictive Markers of Short-Term Sublingual Allergen-Specific Immunotherapy Efficacy in Children with Allergic Rhinitis15
0.14714097976685